50 µg in 0.5 mL dose
Trade Name
Spikevax JN1 50 micrograms
Concentrate for dispersion for injection
Request Type
New Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Spikevax JN1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.